Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cognitive function and platelet membrane fluidity in Alzheimer's disease.

G S Zubenko1, F J Huff, J Becker

  • 1Department of Psychiatry, School of Medicine, University of Pittsburgh, PA.

Biological Psychiatry
|December 1, 1988
PubMed
Summary

Alzheimer's disease patients with increased platelet membrane fluidity show distinct cognitive patterns. Specifically, this subgroup exhibits more left-sided parietal lobe deficits compared to those with normal fluidity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors.

Alimentary pharmacology & therapeutics·2013
Same author

Participants in the workshop.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry·2011
Same author

A user-friendly instrument for rating agitation in dementia patients.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry·2011
Same author

A naturalistic study of trazodone in the treatment of behavioral complications of dementia.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry·2011
Same author

Efficacy and safety study of arbaclofen placarbil in patients with spasticity due to spinal cord injury.

Spinal cord·2011
Same author

The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbil.

International journal of clinical pharmacology and therapeutics·2010

Area of Science:

  • Neuroscience
  • Biochemistry
  • Gerontology

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
  • Platelet membrane fluidity has been investigated as a potential biomarker in AD.
  • A subgroup of AD patients exhibits increased platelet membrane fluidity.

Purpose of the Study:

  • To compare cognitive impairments between Alzheimer's disease patients with increased versus normal platelet membrane fluidity.
  • To investigate specific patterns of cognitive deficits related to parietal lobe function in these subgroups.

Main Methods:

  • Utilized fluorescence anisotropy of diphenylhexatriene to measure platelet membrane fluidity.
  • Assessed cognitive function across six domains in patients meeting NINCDS-ADRDA criteria for AD.

Related Experiment Videos

  • Compared cognitive deficit profiles between subgroups with high and normal platelet membrane fluidity.

    • Main Results:

    • No significant differences in the overall number or distribution of cognitive deficits were found between the two subgroups.
    • Patients with increased platelet membrane fluidity showed a significantly higher incidence of dissociated parietal lobe deficits.
    • Dissociated deficits were predominantly observed as impairments in left parietal lobe function with preserved right parietal lobe function.

    Conclusions:

    • Increased platelet membrane fluidity may identify a clinically distinct subgroup of Alzheimer's disease patients.
    • This subgroup exhibits a specific pattern of cognitive impairment, particularly affecting left parietal lobe functions.
    • Platelet membrane fluidity could serve as a biomarker for specific neuropathological or cognitive profiles in Alzheimer's disease.